The Wall Street Journal’s Kate Odell recently interviewed U.S. Food and Drug Administration Commissioner Scott Gottlieb about his forecast for medicine and regulatory shifts in the U.S.
Gottlieb, who had served as the agency’s deputy commissioner between 2005-2007, is leading the FDA through a key period in medical and payment innovation.
“It used to be that the model was to develop a drug that was going to be administered chronically over the life of a patient,” Gottlieb told Odell. “It was basically an annuity. And now, the model is to try to develop curative therapy.”
Gottlieb said the current payment model “isn’t adapted” to the new therapeutic model.
To read more of the interview on the Wall Street Journal, click here.
